HK1223129A1 - 基因表現生物標記及其於潛在需要組蛋白去乙醯酶抑制劑治療的患者的診斷和預後應用中的使用 - Google Patents

基因表現生物標記及其於潛在需要組蛋白去乙醯酶抑制劑治療的患者的診斷和預後應用中的使用

Info

Publication number
HK1223129A1
HK1223129A1 HK16111295.1A HK16111295A HK1223129A1 HK 1223129 A1 HK1223129 A1 HK 1223129A1 HK 16111295 A HK16111295 A HK 16111295A HK 1223129 A1 HK1223129 A1 HK 1223129A1
Authority
HK
Hong Kong
Prior art keywords
diagnostic
need
gene expression
hdac inhibitor
inhibitor treatment
Prior art date
Application number
HK16111295.1A
Other languages
English (en)
Inventor
Thomas Herz
Hella Kohlhof
Robert Doblhofer
Hans-Peter Hofmann
Martin Elmlinger
Astrid Zimmermann
Elke Staub
Volker Gekeler
Thomas Maier
Marina Mollenhauer-Thein
Markus Bhm
Timo Wittenberger
Thomas Beckers
Original Assignee
4Sc Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Sc Ag filed Critical 4Sc Ag
Publication of HK1223129A1 publication Critical patent/HK1223129A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6816Hybridisation assays characterised by the detection means
    • C12Q1/682Signal amplification
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/978Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/98Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16111295.1A 2013-05-24 2016-09-27 基因表現生物標記及其於潛在需要組蛋白去乙醯酶抑制劑治療的患者的診斷和預後應用中的使用 HK1223129A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361827201P 2013-05-24 2013-05-24
US201361865712P 2013-08-14 2013-08-14
US201461935914P 2014-02-05 2014-02-05
PCT/EP2014/060532 WO2014187894A1 (en) 2013-05-24 2014-05-22 Gene expression biomarkers and their use for diagnostic and prognostic application in patients potentially in need of hdac inhibitor treatment

Publications (1)

Publication Number Publication Date
HK1223129A1 true HK1223129A1 (zh) 2017-07-21

Family

ID=50771295

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16111295.1A HK1223129A1 (zh) 2013-05-24 2016-09-27 基因表現生物標記及其於潛在需要組蛋白去乙醯酶抑制劑治療的患者的診斷和預後應用中的使用

Country Status (12)

Country Link
US (1) US20160215348A1 (zh)
EP (1) EP3004377A1 (zh)
JP (1) JP2016521543A (zh)
KR (1) KR20160010498A (zh)
CN (1) CN105408498A (zh)
AU (1) AU2014270380A1 (zh)
BR (1) BR112015028997A2 (zh)
CA (1) CA2912973A1 (zh)
EA (1) EA201501137A1 (zh)
HK (1) HK1223129A1 (zh)
MX (1) MX2015016114A (zh)
WO (1) WO2014187894A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017034234A1 (ko) * 2015-08-21 2017-03-02 서울대학교 산학협력단 Hdac 억제제 내성을 갖는 암 치료용 복합제제
CN110412268A (zh) * 2018-04-27 2019-11-05 刘晓健 诊断经典霍奇金淋巴瘤的结外累犯的标志物及其应用
CN112691199A (zh) * 2021-01-26 2021-04-23 冠科生物技术(苏州)有限公司 一种预测病患对抑制剂反应的标志物及其使用方法
CN115267165A (zh) * 2022-08-15 2022-11-01 海仕兰(上海)生物科技有限公司 一种悬浮芯片系统及其应用以及基于悬浮芯片系统对肿瘤伴随诊断因子检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859502B2 (en) * 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
CN104056270B (zh) * 2013-02-21 2018-11-09 中国人民解放军军事医学科学院野战输血研究所 用于制备多器官损伤救治药物的组蛋白去乙酰化酶抑制剂

Also Published As

Publication number Publication date
BR112015028997A2 (pt) 2017-10-24
EP3004377A1 (en) 2016-04-13
US20160215348A1 (en) 2016-07-28
KR20160010498A (ko) 2016-01-27
JP2016521543A (ja) 2016-07-25
EA201501137A1 (ru) 2016-06-30
AU2014270380A1 (en) 2015-11-19
CA2912973A1 (en) 2014-11-27
MX2015016114A (es) 2016-07-21
CN105408498A (zh) 2016-03-16
WO2014187894A1 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
IL274174B (en) Ultrasound treatment systems and methods for performing multifocal procedures using them
HK1226161A1 (zh) 動態確定臨床狀況的風險
IL243408A0 (en) Diagnosis and treatment of cancer involving cancer stem cells
IL242825B (en) Systems and methods for diagnosis of depression and other medical conditions
IL242122B (en) Imaging biomarkers for the diagnosis and prognosis of back pain and related conditions
EP2959275A4 (en) DIAGNOSTIC INSTRUMENT AND METHOD
EP2890815A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
AP2016009129A0 (en) Biomarkers for early determination of a critical or life threatening response to illness and/or treatment response
EP3084000A4 (en) Method of diagnosis and treatment
HK1259001A1 (zh) 癌症的預後和診斷方法
RS58834B1 (sr) Mikropeptidi i njihova upotreba za modulaciju ekspresije gena
EP2874647A4 (en) METHOD FOR DIAGNOSIS AND TREATMENT
HK1207968A1 (zh) 抑制劑及其使用方法
HK1215000A1 (zh) 結腸癌的治療和診斷
EP2888370A4 (en) DIAGNOSIS, FORECASTING AND TREATMENT PROCEDURES
EP2991627A4 (en) BLOOD SUCCANTED COMPOSITION AND METHOD OF USE
PL2953539T3 (pl) System i sposób nieinwazyjnego pomiaru miękkiej tkanki biologicznej
HK1223129A1 (zh) 基因表現生物標記及其於潛在需要組蛋白去乙醯酶抑制劑治療的患者的診斷和預後應用中的使用
GB201602663D0 (en) Medical instrument and application thereof
EP3015864A4 (en) Biomarkers for the diagnosis and the response to treatment of pancreatic cancer
HK1225441A1 (zh) 治療和預測脊柱側凸的患者亞群的方法
EP3042955A4 (en) Use of rhoa in cancer diagnosis and inhibitor screening
EP2970154A4 (en) TETRAHYDROXAMATE CHELATORS OF ZIRCONIUM89 AND NIOBIUM90 FOR USE IN DIAGNOSTIC APPLICATIONS
PT2984108T (pt) Anticorpos anti-s100a7 para o tratamento e diagnóstico de cancro
HK1212999A1 (zh) 用於治療和/或限制糖尿病的發展的方法